세계의 만성 통증 치료 시장 : 업계 동향 및 예측 - 적응증별, 분자 유형별, 작용기전별, 주요 지역별

GLOBAL CHRONIC PAIN TREATMENT MARKET: OVERVIEW

As per Roots Analysis, the global chronic pain treatment market valued at USD 7.3 billion in the current year is anticipated to grow at a lucrative CAGR during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Indication

• Chronic Back Pain
• Lumbar Radiculopathy
• Migraine
• Osteoarthritis
• Neuropathic Pain

Type of Molecule

• Small Molecule
• Biologic

Mechanism of Action

• CGRP Inhibitors
• COX/ NGF Inhibitors
• TRPV1 Receptor Antagonists
• Channel Blockers
• Others

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and North Africa

GLOBAL CHRONIC PAIN TREATMENT MARKET: GROWTH AND TRENDS

Chronic pain is a psychophysiological response to an underlying medical condition that persists for more than six months and typically does not respond to various treatment approaches. It is worth mentioning that as per the estimates over 1.5 billion people worldwide experience this form of pain. Notably, opioids remain among the most commonly used pharmacological treatments for moderate to severe pain. This can be attributed to their rapid onset of action and high effectiveness in providing immediate relief. However, opioids can induce feelings of euphoria, which often leads to misuse and addiction. Further, increased recreational use has significantly contributed to the problem of opioid dependency. In fact, according to a 2024 report by CDC's National Center for Health Statistics, 54,743 people died in the United States as a result of misuse of prescribed opioids. The severity of the opioid crisis has driven pharmaceutical companies to focus on developing non-addictive, non-narcotic therapeutics and analgesics for the management of chronic pain.

In contrast to opioids, non-opioid medications do not target brain receptors and are therefore non-addictive. These drugs act directly on injured or diseased tissues, specifically by blocking the production of prostaglandins through inhibition of the cyclooxygenase (COX) enzyme at the site of injury or infection. This mechanism reduces the formation of pain mediators within the peripheral nervous system. Furthermore, a variety of pain management devices have been shown to significantly decrease or even eliminate the need for drug-based treatments.

GLOBAL CHRONIC PAIN TREATMENT MARKET: KEY INSIGHTS

The report delves into the current state of global chronic pain treatment market and identifies potential growth opportunities within industry. Some key findings from the report include:

• With few approved drugs and several clinical / preclinical candidates, the market for non-opioid pain management solutions is growing at a commendable pace.
• Majority (>45%) of the pipeline candidates, having diverse mechanisms of action, are in the early stages of development; the oral route continues to be the preferred mode of drug delivery.

• Given a strong early-stage and preclinical pipeline, the industry is likely to address the current unmet need for non-opioid alternatives with novel biological targets.
• There are several clinical stage receptor agonists designed to target the TRPV1 receptor. Most of the marketed drugs are anti-inflammatory agents and calcium channel blockers.
• Notably, majority (~45%) of the non-opioids for chronic pain management are administered through oral route of administration.
• Benefited by easily blocking ion-channels and antagonizing pain proliferating receptors, the pipeline offers many small molecules in both advanced and preclinical stages.
• Over time, several device-based pain management solutions have also emerged as viable alternatives to narcotic drugs / therapies.
• We identified various devices, based on diverse pain relief technologies, which can be either implanted or superficially applied on the body to provide relief from pain.
• Numerous devices have a competitive advantage by focusing on the pain sensation area; examples of such devices include ActiPatch, BioBeam 940, CareTec IV.
• With friendly user interface, wearable (25%) and hand-held devices (20%) are likely to be adopted by a wide customer base; examples include ElectroCore and Interx Technologies.
• Although the market is characterized with multiple stimulation-based devices, next generation devices focus on innovative and less invasive mechanisms for pain relief.
• In pursuit of gaining a competitive edge, manufacturers are focusing on the integration of advanced features in their respective product portfolios.
• Companies have raised significant amounts in financing as investors have realized numerous benefits and future potential for non-opioid alternatives to chronic pain.
• Investments in various companies have fostered innovation in this domain; examples include Centrexion Therapeutics, Hydra Bioscience, NeurogesX and Vapogenix.
• The significant share of investments was raised by stakeholders through various rounds of venture capital funding, primarily in venture series B.
• Multiple investors have supported the initiatives of non-opioid drug developers; huge amount has been awarded only by NIH in the domain.
• With the growing interest in the field of chronic pain therapeutics, several partnerships have been established between device providers and other stakeholders. Notably, most (>25%) of the partnerships were commercialization agreements.

• Prevalent trends indicate that the market is likely to grow at a significant pace as multiple late-stage molecules receive marketing approval in the foreseen future.

Example Players in the Chronic Pain Treatment Market

• Stimwave
• BlueWind Medical
• Omron Healthcare
• Cefaly Technologies
• Prizm Medical
• PainPod
• Neurometrix
• Chattem
• Silk'n Therapy
• ElectroMedical Technologies

PRIMARY RESEARCH OVERVIEW

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews conducted with the following industry stakeholders:

• Chief Executive Officer, Company A
• Chief Advocacy Officer, Company B
• Chief Executive Officer, Company C
• Director of Clinical Affairs and New Markets, Company D

GLOBAL CHRONIC PAIN TREATMENT MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global chronic pain treatment market, focusing on key market segments, including [A] type of indication, [B] type of molecule, [C] mechanism of action and [D] key geographical regions.
• Drugs Market Landscape: A comprehensive evaluation of drugs being developed for the treatment of chronic pain, considering various parameters, such as [A] information on their respective developer(s), [B] phase of development, [C] type of molecule, [D] indication, [E] mechanism of action and [F] route of administration.
• Pipeline Review of Marketed and Development Drugs: A detailed analysis of product pipeline and developer companies, highlighting [A] a mirror analysis depicting the relative popularity of different disease indications based on the number of molecules available / under development for each indication and the number of companies involved, [B] a comprehensive analysis of the various industry players involved in chronic pain treatment market, distributed on the basis of location of headquarters and company size, [C] a detailed analysis highlighting the distribution of marketed and pipeline molecules based on their respective mechanisms of action, and [D] an analysis highlighting the distribution of molecules on the basis of stage of development, route of administration and treatment type.
• Unmet Need Analysis: A comprehensive evaluation of the key unmet needs across chronic pain, highlighting insights generated from data sourced from [A] patient blogs, [B] recent scientific publications, [C] social media posts and [D] the views of key opinion leaders expressed on various online platforms.
• Lifecycle Management Strategies for Marketed Products: A detailed discussion on the lifecycle management strategies that describes how various companies are using different methods to prolong patent age and, thereby, expand marketing exclusivity in order to exploit the revenue generation potential of their proprietary products.
• Drug Profiles: In-depth profiles of drugs that are in phase III of clinical development, focusing on [A] information on developer companies, [B] type of molecule, [C] mechanism of action, [D] current status of development, [E] route of administration, [F] information on clinical trials and [G] key developments (if available).
• Chronic Pain Management Devices Market Landscape: A comprehensive evaluation of various devices that are being developed for chronic pain management, considering various parameters, such as [A] information on developer(s), [B] mechanism of action, [C] site of application on the body, [D] modality of the device, [E] treatment requirements and [F] type of device.
• Device Competitiveness Analysis and Profiles: A comprehensive device competitive analysis highlighting the most important products by examining factors, such as [A] modality of device, [B] treatment requirement, [C] type of device and [D] supplier power. Furthermore, in-depth profiles of devices that emerged as relatively superior, focusing on [A] details on the developer, [B] approval year, [C] mechanism of action, [D] key features and [E] key developments.
• Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the chronic pain treatment market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] quarterly trends, [D] most active players (in terms of the number of partnerships signed) and [E] geography.
• Funding and Investments: An insightful analysis of investments made at various stages of product development, based on various relevant parameters, such as [A] types of funding, [B] amount invested, [C] most active players and [D] most active investors.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Definition of Pain
• 3.2. Classification of Pain
  • 3.2.1. Acute Pain
  • 3.2.2. Chronic Pain
    • 3.2.2.1. Classification of Chronic Pain
    • 3.2.2.2. Chronic Pain and Mental Health
• 3.3. Pain Management
  • 3.3.1. Therapeutics for Pain Management
  • 3.3.2. Devices for Pain Management
  • 3.3.3. Other Therapeutic Modalities and Interventions for Pain Management
• 3.4. Future Prospects

4. CHRONIC PAIN MANAGEMENT: UNMET NEED ANALYSIS

• 4.1. Chapter Overview
• 4.2. Unmet Need Analysis
  • 4.2.1. Introduction
  • 4.2.2. Patient Blogs
    • 4.2.2.1. Methodology
    • 4.2.2.2. Key Insights
  • 4.2.3. Published Literature
    • 4.2.3.1. Methodology
    • 4.2.3.2. Key Insights
  • 4.2.4. Social Media Platforms
    • 4.2.4.1. Methodology
    • 4.2.4.2. Key Insights
  • 4.2.5. Expert Opinions
    • 4.2.5.1. Jeffrey Curtis, MD, University of Alabama
    • 4.2.5.2. Stephan Silberstein, MD, Jefferson University Hospital
    • 4.2.5.3. Jeffrey Gudin, MD, Englewood Hospital and Medical Center
    • 4.2.5.4. Kevin Zacharoff, MD, SUNY Stonybrook School of Medicine
    • 4.2.5.5. Philip J Mease, MD, University of Washington School of Medicine
    • 4.2.5.6. John D Reveille, MD, McGovern Medical School
    • 4.2.5.7. Christopher R McCurdy, PhD, University of Florida
  • 4.2.6. Concluding Remarks: Key Unmet Needs in Chronic Pain Management

5. PIPELINE REVIEW: MARKETED AND DEVELOPMENT DRUGS

• 5.1. Chapter Overview
• 5.2. Non-Opioid Drugs for Chronic Pain Management: Marketed and Development Pipeline
• 5.3. Non-Opioid Drugs for Chronic Pain Management: Pipeline Analysis
  • 5.3.1. Analysis by Phase of Development
  • 5.3.2. Analysis by Type of Molecule
  • 5.3.3. Analysis by Mechanism of Action
  • 5.3.4. Analysis by Route of Administration
  • 5.3.5. Analysis by Target Therapeutic Indication(s)
  • 5.3.6. Analysis by Size of Employee Base of Developer
  • 5.3.7. Pipeline Analysis: Leading Players
  • 5.3.8. Developer Logo Landscape: Distribution by Size and Location
  • 5.3.9. Mirror Analysis: Distribution by Type of Indication, Number of Molecules and Manufacturer
  • 5.3.10. Heptagon Representation: Distribution by Target Disease Indication and Phase of Development
  • 5.3.11. Funnel Analysis: Distribution by Target Disease Indications, Route of Administration and Phase of Development

6. LIFECYCLE MANAGEMENT STRATEGIES FOR MARKETED PRODUCTS

• 6.1. Introduction
• 6.2. Product Profile: Duexis(R) (Horizon Pharma)
  • 6.2.1. Overview
  • 6.2.2. Mechanism of Action
  • 6.2.3. Life Cycle Management Strategies
    • 6.2.3.1. Strategic Pricing
    • 6.2.3.2. Geographical Expansion
    • 6.2.3.3. Indication Expansion
    • 6.2.3.4. Extension of Patent Exclusivity
    • 6.2.3.5. Authorized Generics
    • 6.2.3.6. Awareness Campaigns
  • 6.2.4. Partnerships and Collaborations
    • 6.2.4.1. Mallinckrodt
    • 6.2.4.2. Gru nenthal
• 6.3. Product Profile: Gralise(R) (Depomed)
  • 6.3.1. Overview
  • 6.3.2. Mechanism of Action
  • 6.3.3. Life Cycle Management Strategies
    • 6.3.3.1. New Dose Strength
  • 6.3.4. Legal Defense
    • 6.3.4.1. Authorized Generics
  • 6.3.5. Partnerships and Collaborations
    • 6.3.5.1. Actavis
    • 6.3.5.2. Abbott
• 6.4. Product Profile: Horizant(R) (Arbor Pharmaceuticals)
  • 6.4.1. Overview
  • 6.4.2. Mechanism of Action
  • 6.4.3. Life Cycle Management Strategies
    • 6.4.3.1. Extension of Patent Exclusivity
    • 6.4.3.2. Indication Expansion
  • 6.4.4. New Dose Strength
  • 6.4.5. Partnerships and Collaborations
    • 6.4.5.1. GlaxoSmithKline
    • 6.4.5.2. Arbor Pharmaceutical
• 6.5. Product Profile: Vimovo(R) (AstraZeneca and Pozen)
  • 6.5.1. Overview
  • 6.5.2. Mechanism of Action
  • 6.5.3. Life Cycle Management Strategies
    • 6.5.3.1. Pricing
    • 6.5.3.2. Geographical Expansion
  • 6.5.4. Legal Defense
  • 6.5.5. Partnerships and Collaborations
    • 6.5.5.1. AstraZeneca
    • 6.5.5.2. Horizon Pharma

7. DRUG PROFILES: LATE-STAGE MOLECULES

• 7.1. Chapter Overview
• 7.2. Drug Profile: Aimovig(TM) / Erenumab
• 7.3. Drug Profile: Analgecine
• 7.4. Drug Profile: Atogepant / AGN 241689 / MK 8031
• 7.5. Drug Profile: Civamide / Civanex / Zucapsaicin
• 7.6. Drug Profile: CNTX-4975
• 7.7. Drug Profile: Eptinezumab / ALD403
• 7.8. Drug Profile: Fasinumab
• 7.9. Drug Profile: Fremanezumab
• 7.10. Drug Profile: Galcanezumab / LY2951742
• 7.11. Drug Profile: Lasmiditan / COL-144
• 7.12. Drug Profile: Mirogabalin / DS-5565
• 7.13. Drug Profile: MPC-06-ID
• 7.14. Drug Profile: Neridronate
• 7.15. Drug Profile: NTM-001
• 7.16. Drug Profile: NTM-002
• 7.17. Drug Profile: Perampanel (E2007)
• 7.18. Drug Profile: POSIMIR (SABER-Bupivacaine)
• 7.19. Drug Profile: Ralfinamide
• 7.20. Drug Profile: SP-102
• 7.21. Drug Profile: T-121
• 7.22. Drug Profile: Tanezumab
• 7.23. Drug Profile: Tetrodotoxin / TTX
• 7.24. Drug Profile: Ubrogepant / MK-1602
• 7.25. Drug Profile: YHD1119 / PREGABALIN

8. CHRONIC PAIN MANAGEMENT DEVICES: MARKET LANDSCAPE

• 8.1. Chapter Overview
• 8.2. Devices for Pain Management: Database
• 8.3. Devices for Pain Management: Database Analysis
  • 8.3.1. Analysis by Type of Devices
  • 8.3.2. Analysis by Mechanism of Action
  • 8.3.3. Analysis by Modality of Device
  • 8.3.4. Analysis by Site of Application on Body
  • 8.3.5. Analysis by Convenience of Use
  • 8.3.6. Analysis by Location of Developer(s)
  • 8.3.7. Analysis by Company Size

9. DEVICE COMPETITIVENESS ANALYSIS AND PROFILES

• 9.1. Chapter Overview
• 9.2. Methodology
• 9.3. Implants
  • 9.3.1. Assumptions, Limitations and Key Evaluable Parameters
  • 9.3.2. Device Competitive Analysis for Implants: Results
  • 9.3.3. Device Profiles
    • 9.3.3.1. Freedom SCS System (Stimwave)
    • 9.3.3.2. VIVENDI(TM) (BlueWind Medical)
• 9.4. Wearables
  • 9.4.1. Assumptions, Limitations and Parameters Evaluated
  • 9.4.2. Device Competitive Analysis for Wearables: Results
  • 9.4.3. Device Profiles
    • 9.4.3.1. Avail Wireless (Omron Healthcare)
    • 9.4.3.2. Cefaly (Cefaly Technologies)
    • 9.4.3.3. Electro-Mesh Garments (Prizm Medical)
    • 9.4.3.4. Micro-Z (Prizm Medical)
    • 9.4.3.5. PainPod MI (PainPod)
    • 9.4.3.6. PainPod XPV (PainPod)
    • 9.4.3.7. Quell Relief (Neurometrix)
    • 9.4.3.8. SENSUS(R) Pain Management System (Neurometrix)
    • 9.4.3.9. Smart Relief Back (Chattem)
• 9.5. Other Devices
  • 9.5.1. Assumptions, Limitations and Parameters Evaluated
  • 9.5.2. Devices Competitive Analysis for Other Devices: Results
  • 9.5.3. Device Profiles
    • 9.5.3.1. Silk'n Relief (Silk'n Therapy)
    • 9.5.3.2. The Wellness Pro(TM) Plus (ElectroMedical Technologies)

10. PARTNERSHIPS AND COLLABORATIONS

• 10.1. Chapter Overview
• 10.2. Partnership Models
• 10.3. Non-Opioid Drugs and Devices for Chronic Pain Management: Recent Partnerships and Collaborations
  • 10.3.1. Analysis by Year of Agreement
  • 10.3.2. Analysis by Quarterly Trends
  • 10.3.3. Analysis by Type of Partnership
  • 10.3.4. Analysis by Most Active Players
  • 10.3.5. Analysis by Geographical Activity

11. FUNDING AND INVESTMENT ANALYSIS

• 11.1. Chapter Overview
• 11.2. Types of Funding
• 11.3. Non-Opioid Drugs for Chronic Pain Management: Funding and Investment Analysis
  • 11.3.1. Analysis by Cumulative Number of Funding Instances
  • 11.3.2. Analysis by Cumulative Amount Invested
  • 11.3.3. Analysis by Type of Funding
  • 11.3.4. Analysis by Most Active Players
  • 11.3.5. Analysis by Most Active Investors
• 11.4. Concluding Remarks

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 12.1. Chapter Overview
• 12.2. Key Assumptions
• 12.3. Forecast Methodology
• 12.4. Overall Non-Opioids Drugs for Chronic Pain Management Market, Since 2018
  • 12.4.1. Non-Opioid Drugs Market: Distribution by Therapeutic Area
  • 12.4.2. Non-Opioid Drugs Market: Distribution by Molecule Type
  • 12.4.3. Non-Opioid Drugs Market: Distribution by Mechanism of Action
  • 12.4.4. Non-Opioid Drugs Market: Distribution by Geography
• 12.5. Non-Opioid Drugs Market: Product-Wise Sales Forecasts
  • 12.5.1. Qutenza(R) (Accorda Therapeutics)
    • 12.5.1.1. Drug Overview and Target Patient Population
    • 12.5.1.2. Sales Forecast
  • 12.5.2. Vimovo(R) (Horizon Pharma)
    • 12.5.2.1. Drug Overview and Target Patient Population
    • 12.5.2.2. Sales Forecast
  • 12.5.3. Duexis(R) (Horizon Pharma)
    • 12.5.3.1. Drug Overview and Target Patient Population
    • 12.5.3.2. Sales Forecast
  • 12.5.4. Gralise(R) (Depomed)
    • 12.5.4.1. Drug Overview and Target Patient Population
    • 12.5.4.2. Sales Forecast
  • 12.5.5. Horizant(R) (Arbor Pharmaceuticals)
    • 12.5.5.1. Drug Overview and Target Patient Population
    • 12.5.5.2. Sales Forecast
  • 12.5.6. Zilretta(R) (Flexion Therapeutics)
    • 12.5.6.1. Drug Overview and Target Patient Population
    • 12.5.6.2. Sales Forecast
  • 12.5.7. Ztlido(TM) (Sorrento Therapeutics)
    • 12.5.7.1. Drug Overview and Target Patient Population
    • 12.5.7.2. Sales Forecast
  • 12.5.8. Aimovig(TM) (Amgen)
    • 12.5.8.1. Drug Overview and Target Patient Population
    • 12.5.8.2. Sales Forecast
  • 12.5.9. Fremanezumab (Teva Pharmaceuticals)
    • 12.5.9.1. Drug Overview and Target Patient Population
    • 12.5.9.2. Sales Forecast
  • 12.5.10. Galcanezumab (Eli Lilly)
    • 12.5.10.1. Drug Overview and Target Patient Population
    • 12.5.10.2. Sales Forecast
  • 12.5.11. Mirogabalin (DS-5565) (Daiichi Sankyo)
    • 12.5.11.1. Drug Overview and Target Patient Population
    • 12.5.11.2. Sales Forecast
  • 12.5.12. YHD1119 (Yuhan corporation)
    • 12.5.12.1. Drug Overview and Target Patient Population
    • 12.5.12.2. Sales Forecast
  • 12.5.13. GLA5PR (GL PharmTech)
    • 12.5.13.1. Drug Overview and Target Patient Population
    • 12.5.13.2. Sales Forecast
  • 12.5.14. Eptinezumab (Alder Biopharmaceuticals)
    • 12.5.14.1. Drug Overview and Target Patient Population
    • 12.5.14.2. Sales Forecast
  • 12.5.15. ALLOD-2 (Allodynic Therapeutics)
    • 12.5.15.1. Drug Overview and Target Patient Population
    • 12.5.15.2. Sales Forecast
  • 12.5.16. PainBrake(R) (GT Biopharma)
    • 12.5.16.1. Drug Overview and Target Patient Population
    • 12.5.16.2. Sales Forecast
  • 12.5.17. Neridronate (Grunenthal)
    • 12.5.17.1. Drug Overview and Target Patient Population
    • 12.5.17.2. Sales Forecast
  • 12.5.18. Fasinumab (Regeneron Pharmaceuticals)
    • 12.5.18.1. Drug Overview and Target Patient Population
    • 12.5.18.2. Sales Forecast
  • 12.5.19. SP-102 (Semnur Pharmaceuticals)
    • 12.5.19.1. Drug Overview and Target Patient Population
    • 12.5.19.2. Sales Forecast
  • 12.5.20. CNTX-4975 (Centrexion Therapeutics)
    • 12.5.20.1. Drug Overview and Target Patient Population
    • 12.5.20.2. Sales Forecast
  • 12.5.21. MPC-06-ID (Mesoblast)
    • 12.5.21.1. Drug Overview and Target Patient Population
    • 12.5.21.2. Sales Forecast
  • 12.5.22. Tanezumab
    • 12.5.22.1. Drug Overview and Target Patient Population
    • 12.5.22.2. Sales Forecast
• 12.6. Overall Pain Management Devices Market, Since 2018
  • 12.6.1. Pain Management Devices Market: Distribution by Geography
  • 12.6.2. Pain Management Devices Market: Distribution by Type of Device
  • 12.6.3. Pain Management Devices Market: Distribution by Mechanism of Action

13. CONCLUSION

• 13.1. The Opioid Crisis is Responsible for a Number of Fatalities Due to the Abuse of Controlled Substances; Drug Developers are Actively Attempting to Develop Alternative Pain Management Solutions
• 13.2. The Non-Opioid Therapeutics Market is Characterized by a Robust Pipeline of Candidate Drugs Being Developed for a Variety of Chronic Clinical Conditions
• 13.3. A Variety of Innovative Devices are also Available for the Management of Various Clinical Conditions Characterized by Chronic Pain
• 13.4. Increasing Partnership Activity and Financial Support from Various Investors are Indicative of Lucrative Future Potential
• 13.5. Given the Existing Unmet Needs, the Market is Anticipated to Grow at a Steady Pace in the Foreseen Future

14. EXECUTIVE INSIGHTS

• 14.1. Chapter Overview
• 14.2. Chief Executive Officer, Company A
• 14.3. Chief Advocacy Officer, Company B
• 14.4. Chief Executive Officer, Company C
• 14.5. Director of Clinical Affairs and New Markets, Company D

15. APPENDIX I

16. APPENDIX II